Replies to post #9449 on Avid Bioservices Inc (CDMO)

[jakedogman1]

I spoke with someone at IR several weeks ago. I mentioned the Oct 30 presention as a key date. The response was that Oct 30 was important but the real value drivers will be repeat dose data and combo therapy data.

[DewDiligence]

>That leaves me wondering about what is your point?<

Sorry for being unclear—let me spell it out more plainly.

I think the notion that Bavi monotherapy can become the standard of care in the treatment of chronic HCV is patently absurd.

If anyone not affiliated with PPHM says that this is a realistic possibly, I would like to know about it. Regards, Dew